Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.9413
+0.0833 (9.71%)
Oct 9, 2025, 11:25 AM EDT - Market open
Cue Biopharma Revenue
Cue Biopharma had revenue of $2.95M in the quarter ending June 30, 2025, with 11.14% growth. This brings the company's revenue in the last twelve months to $8.29M, down -0.11% year-over-year. In the year 2024, Cue Biopharma had annual revenue of $9.29M with 69.16% growth.
Revenue (ttm)
$8.29M
Revenue Growth
-0.11%
P/S Ratio
7.65
Revenue / Employee
$202,098
Employees
41
Market Cap
72.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CUE News
- 10 days ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 7 weeks ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 3 months ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 3 months ago - Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - GlobeNewsWire
- 5 months ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire